US Attorney scrutinizes Copaxone marketing

Share this article:

The US Attorney's Office for the Southern District of New York is looking into how Teva marketed its MS drug Copaxone and Parkinson's medication Azilect since 2006. The Associated Press reports that the drugmaker announced the investigation Monday and is exploring “possible violations of the False Claims Act.” Citi research analyst Liav Abraham told the AP that the FDA has increased its False Claims investigations over the past few years and that they can take several years to wrap.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.